Today, the Co-CEO & President of Pluristem (PSTI), Yaky Yanay, bought shares of PSTI for $50K.
In addition to Yaky Yanay, 5 other PSTI executives reported Buy trades in the last month. Following this transaction Yaky Yanay’s holding in the company was increased by 1.68% to a total of $2.5 million.
See today’s analyst top recommended stocks >>
Based on Pluristem’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $50K and GAAP net loss of $8.68 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $1.53 million. Currently, Pluristem has an average volume of 1.93M.
Starting in April 2018, PSTI received 21 Buy ratings in a row.
Yaky Yanay’s trades have generated a -17.8% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.
